Evidence map›Paper›PMID 42111367›Full record

ArticleACG case reports journal2026

Phenobarbital Treatment for Prolonged Cholestatic Jaundice After Endoscopic Retrograde Cholangiopancreatography.

Takumi Yoneyama, Toru Matsui, Oki Nakano, Hiromitsu Oka, Yutaka Honda, Masaaki Takamura

Abstract readCase Reports
In one paragraph

Article in ACG case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Takumi YoneyamaDepartment of Gastroenterology, Nagaoka Chuo General Hospital, Niigata, Japan.
Toru MatsuiDepartment of Gastroenterology, Nagaoka Chuo General Hospital, Niigata, Japan.
Oki NakanoDepartment of Gastroenterology, Nagaoka Chuo General Hospital, Niigata, Japan.
Hiromitsu OkaDepartment of Gastroenterology, Nagaoka Chuo General Hospital, Niigata, Japan.
Yutaka HondaDepartment of Gastroenterology, Nagaoka Chuo General Hospital, Niigata, Japan.
Masaaki TakamuraDepartment of Gastroenterology, Nagaoka Chuo General Hospital, Niigata, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prolonged cholestatic jaundice after endoscopic retrograde cholangiopancreatography (ERCP) is a rare and clinically challenging condition when mechanical obstruction is excluded. While its pathophysiology remains unclear and no established treatment strategy exists, we describe a patient with persistent post-ERCP cholestasis whose hyperbilirubinemia improved markedly after initiation of phenobarbital. The total bilirubin level decreased from a peak of 29.8 mg/dL to 23.9 mg/dL within 5 days and continued to decline thereafter. This suggests that phenobarbital could be a potential therapeutic option for prolonged post-ERCP cholestasis when conventional treatments, such as ursodeoxycholic acid and herbal medicine, are ineffective.

Indexed as

endoscopic retrograde cholangiopancreatographyphenobarbitalpost-ERCP cholestasisprolonged cholestatic jaundice

Identifiers

PMID42111367
PMCPMC13152220

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.